These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9353037)

  • 1. Induction of an immune response by oral administration of recombinant botulinum toxin.
    Kiyatkin N; Maksymowych AB; Simpson LL
    Infect Immun; 1997 Nov; 65(11):4586-91. PubMed ID: 9353037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
    Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
    Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.
    Clayton MA; Clayton JM; Brown DR; Middlebrook JL
    Infect Immun; 1995 Jul; 63(7):2738-42. PubMed ID: 7790092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
    Gao YL; Gao S; Kang L; Nie C; Wang JL
    Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of immunodetection system for botulinum neurotoxin type B using synthetic gene based recombinant protein.
    Jain S; Ponmariappan S; Kumar O
    Indian J Med Res; 2011 Jul; 134(1):33-9. PubMed ID: 21808132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.
    Sayadmanesh A; Ebrahimi F; Hajizade A; Rostamian M; Keshavarz H
    Iran Biomed J; 2013; 17(4):165-70. PubMed ID: 23999711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
    Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.
    Valipour E; Moosavi ML; Amani J; Nazarian S
    World J Microbiol Biotechnol; 2014 Jun; 30(6):1861-7. PubMed ID: 24469548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component.
    Mahmut N; Inoue K; Fujinaga Y; Arimitsu H; Sakaguchi Y; Hughes L; Hirst R; Murphy T; Tsuji T; Watanabe T; Ohyama T; Karasawa T; Nakamura S; Yokota K; Oguma K
    J Med Microbiol; 2002 Oct; 51(10):813-820. PubMed ID: 12435059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effective expression of fragments of a botulinum neurotoxin type A gene, coding for the L-chain and H-chain in E. coli, with formation of products causing protective immunity to administration of the toxin].
    Vertiev IuV; Zdanovskiĭ AG; Borinskaia SA; Martin T; Gening EL; Iankovskiĭ NK
    Mol Gen Mikrobiol Virusol; 2000; (4):3-7. PubMed ID: 11186457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment.
    Foynes S; Holley JL; Garmory HS; Titball RW; Fairweather NF
    Vaccine; 2003 Mar; 21(11-12):1052-9. PubMed ID: 12559779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin.
    Holley JL; Elmore M; Mauchline M; Minton N; Titball RW
    Vaccine; 2000 Sep; 19(2-3):288-97. PubMed ID: 10930684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
    Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
    Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E.
    Mansour AA; Mousavi SL; Rasooli I; Nazarian S; Amani J; Farhadi N
    Biologicals; 2010 Mar; 38(2):260-4. PubMed ID: 19879159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, purification and development of neutralizing antibodies from synthetic BoNT/B LC and its application in detection of botulinum toxin serotype B.
    Ponmariappan S; Jain S; Sijoria R; Tomar A; Kumar O
    Protein Pept Lett; 2012 Mar; 19(3):288-98. PubMed ID: 21933129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.